Your browser doesn't support javascript.
loading
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Yang, Hongbing; Llano, Anuska; Cedeño, Samandhy; von Delft, Annette; Corcuera, Angelica; Gillespie, Geraldine M; Knox, Andrew; Leneghan, Darren B; Frater, John; Stöhr, Wolfgang; Fidler, Sarah; Mothe, Beatriz; Mak, Johnson; Brander, Christian; Ternette, Nicola; Dorrell, Lucy.
Afiliação
  • Yang H; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK; National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford OX4 2PG, UK; Research In Viral Eradication of Reservoirs (RIVER) trial study group. Electronic address: hongbing.yang@ndm.
  • Llano A; Irsicaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
  • Cedeño S; Irsicaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
  • von Delft A; National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford OX4 2PG, UK; Centre for Medicines Discovery, University of Oxford, Oxford, UK.
  • Corcuera A; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Gillespie GM; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Knox A; Immunocore Ltd, Milton, Abingdon OX14 4RY, UK.
  • Leneghan DB; Immunocore Ltd, Milton, Abingdon OX14 4RY, UK.
  • Frater J; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK; National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford OX4 2PG, UK; Research In Viral Eradication of Reservoirs (RIVER) trial study group.
  • Stöhr W; Medical Research Council Clinical Trials Unit, University College London, London WC1V 6LJ, UK; Research In Viral Eradication of Reservoirs (RIVER) trial study group.
  • Fidler S; Department of Infectious Disease, Imperial College London, National Institute for Health Research Imperial Biomedical Research Centre, London W2 1NY, UK; Research In Viral Eradication of Reservoirs (RIVER) trial study group.
  • Mothe B; Irsicaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain; Faculty of Medicine, Universitat de Vic-Central de Catalunya (UVic-UCC), 08500 Vic, Spain; Fundació Lluita contra la Sida, Infectious Disease Department, Hospital Universitari Germans Trias
  • Mak J; Institute for Glycomics, Griffith University Gold Coast, Southport QLD 4215, Australia.
  • Brander C; Irsicaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain; Faculty of Medicine, Universitat de Vic-Central de Catalunya (UVic-UCC), 08500 Vic, Spain; Institució Catalana de Recerca I Estudis Avançats (ICREA), 08010 Barcelona, Spain.
  • Ternette N; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Dorrell L; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK; National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford OX4 2PG, UK; Immunocore Ltd, Milton, Abingdon OX14 4RY, UK; Research In Viral Eradication of Reservoirs (RIVER) trial stud
Cell Rep ; 35(6): 109103, 2021 05 11.
Article em En | MEDLINE | ID: mdl-33979627
ABSTRACT
Persistence of HIV through integration into host DNA in CD4+ T cells presents a major barrier to virus eradication. Viral integration may be curtailed when CD8+ T cells are triggered to kill infected CD4+ T cells through recognition of histocompatibility leukocyte antigen (HLA) class I-bound peptides derived from incoming virions. However, this has been reported only in individuals with "beneficial" HLA alleles that are associated with superior HIV control. Through interrogation of the pre-integration immunopeptidome, we obtain proof of early presentation of a virion-derived HLA-A∗0201-restricted epitope, FLGKIWPSH (FH9), located in Gag Spacer Peptide 2 (SP2). FH9-specific CD8+ T cell responses are detectable in individuals with primary HIV infection and eliminate HIV-infected CD4+ T cells prior to virus production in vitro. Our data show that non-beneficial HLA class I alleles can elicit an effective antiviral response through early presentation of HIV virion-derived epitopes and also demonstrate the importance of SP2 as an immune target.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Peptídeos / Vírion / Infecções por HIV / Linfócitos T CD8-Positivos Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Peptídeos / Vírion / Infecções por HIV / Linfócitos T CD8-Positivos Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article